Gemini Jets Domodedovo (Russia) Ilyushin IL-62M GJDMO873 1/400 REG# RA-86519 New Other Airline Collectibles


  1. Home
  2. Gemini Jets Domodedovo (Russia) Ilyushin IL-62M GJDMO873 1/400 REG# RA-86519 New
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
Gemini Jets Domodedovo (Russia) Ilyushin IL-62M GJDMO873 1/400 REG# RA-86519 New
Condition: New: A brand-new, unused, unopened, undamaged item (including handmade items). See the seller's Brand:

Gemini Jets

Aircraft Family: IL-62 Scale: 1:400
Recommended Age Range: 14+ Vehicle Make: Kazan Aircraft Production Association / KAPO
Gender: Boys & Girls Vehicle Type: Commercial Airliner
Country/Region of Manufacture: China Material: Diecast
Airline: Domodedovo Airlines (Russia) Model:

Ilyushin IL-62M

Registration: RA-86519 MPN:

GJDMO873

UPC:

763116708733







published on tue nov 09 2021

Gemini Jets Domodedovo (Russia) Ilyushin IL-62M GJDMO873 1/400 REG# RA-86519 New Other Airline Collectibles

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

Gemini Jets Domodedovo (Russia) Ilyushin IL-62M GJDMO873 1/400 REG# RA-86519 New Other Airline Collectibles

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS